News

Muronomab-CD3, also known by its trade name Orthoclone OKT3, is historically significant as it was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for use in humans in 1986, for the prevention of kidney transplant rejection. This groundbreaking development not only demonstrated the potential of mAbs in clinical practice but also set the foundation for future research and therapeutic strategies. 

Bispecific antibody-drug conjugates (bsADCs) are an emerging class of therapeutics that combine the dual-targeting capabilities of bispecific antibodies (bsAbs) with the potent cytotoxic action of antibody-drug conjugates (ADCs). This innovative, next-generation ADC approach aims to enhance the selectivity and efficacy of cancer treatments, offering new hope in the fight against complex malignancies. As of January 2024, there are 10 bsADCs in clinical trials, but none are approved fully yet.

Chongqing, China – From 16 to 18 March 2024, the bustling halls of Chongqing International Expo Center witnessed a remarkable convergence of innovations and advancements, as the 21st China Association of Clinical Laboratory Practice Expo (CACLP) and the 4th edition of China IVD Supply Chain Expo (CISCE) concluded with resounding success.  Occupying an expansive 130,000 sqm exhibiting area across

Could you please give our readers a brief overview of your role and your background? I am the Vice President of Quality and Regulatory Management at Tecan. I have worked at Tecan for over 10 years, and have over 30 years of experience in the IVD industry. What is IVDR, and what is the timeline

OVID-19 created unprecedented demand for in vitro diagnostic expertise and products, and Kalorama Information’s latest market research report provides a guide to the past, present, and future of the IVD market. ARLINGTON, Va., Aug. 31, 2023 /PRNewswire/ — In vitro diagnostics (IVDs) remain dynamic. The IVD market is a high R&D spend industry with constant innovations and